London-based Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, is committed to advancing therapies for autoimmune and inflammatory diseases. Its flagship product offering, nomacopan, a second-generation complement inhibitor, is designed to attenuate the effects of inflammation and thrombosis characteristic to ailments such as paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.